NRX-101 is an oral, fixed-dose combination therapy that incorporates D-cycloserine and lurasidone. It is specifically being developed for the treatment of suicidal bipolar depression and has received the esteemed FDA Breakthrough Therapy designation, which indicates its potential to offer significant improvements over existing treatment options.